$2.36 Billion is the total value of NEA Management Company, LLC's 54 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALLK | ALLAKOS INC | $184,744,000 | +13.3% | 2,268,188 | 0.0% | 7.82% | +19.4% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCadr | $136,319,000 | -20.3% | 17,082,611 | 0.0% | 5.77% | -16.0% | |
| OYST | OYSTER PT PHARMA INC | $125,083,000 | -26.9% | 5,925,287 | 0.0% | 5.30% | -23.0% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $106,450,000 | -2.8% | 4,912,306 | 0.0% | 4.51% | +2.3% | |
| BDTX | BLACK DIAMOND THERAPEUTICS INC | $104,289,000 | -28.3% | 3,449,845 | 0.0% | 4.42% | -24.5% | |
| AKUS | AKOUOS INC | $98,306,000 | +1.6% | 4,298,488 | 0.0% | 4.16% | +7.0% | |
| IMRA | IMARA INC | $81,709,000 | -26.4% | 4,017,170 | 0.0% | 3.46% | -22.5% | |
| TRILLIUM THERAPEUTICS INC | $81,514,000 | +75.7% | 5,736,363 | 0.0% | 3.45% | +84.9% | ||
| MIRM | MIRUM PHARMACEUTICALS INC | $80,699,000 | -1.0% | 4,187,801 | 0.0% | 3.42% | +4.3% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $76,194,000 | -9.4% | 5,172,683 | 0.0% | 3.23% | -4.5% | |
| ARDX | ARDELYX INC | $71,576,000 | -24.1% | 13,633,582 | 0.0% | 3.03% | -20.1% | |
| GRTX | GALERA THERAPEUTICS INC | $39,441,000 | +26.6% | 4,362,986 | 0.0% | 1.67% | +33.4% | |
| GLYC | GLYCOMIMETICS INC | $27,903,000 | -18.4% | 9,089,041 | 0.0% | 1.18% | -14.0% | |
| MEIP | MEI PHARMA INC | $26,623,000 | -24.5% | 8,533,072 | 0.0% | 1.13% | -20.5% | |
| BE | BLOOM ENERGY CORP | $23,960,000 | +65.2% | 1,333,333 | 0.0% | 1.02% | +74.1% | |
| TRVI | TREVI THERAPEUTICS INC | $23,941,000 | -38.8% | 5,940,796 | 0.0% | 1.01% | -35.5% | |
| AVEO | AVEO PHARMACEUTICALS INC | $23,481,000 | +15.3% | 3,952,958 | 0.0% | 0.99% | +21.5% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $23,319,000 | -23.7% | 6,643,704 | 0.0% | 0.99% | -19.7% | |
| AFMD | AFFIMED NV | $20,769,000 | -26.5% | 6,126,488 | 0.0% | 0.88% | -22.7% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $15,852,000 | -3.2% | 1,713,720 | 0.0% | 0.67% | +1.8% | |
| CTIC | CTI BIOPHARMA CORP | $15,352,000 | +85.3% | 7,140,450 | 0.0% | 0.65% | +95.2% | |
| LQDA | LIQUIDIA TECHNOLOGIES INC | $12,231,000 | -41.6% | 2,486,062 | 0.0% | 0.52% | -38.5% | |
| TRVN | TREVENA INC | $11,397,000 | +99.3% | 3,811,691 | 0.0% | 0.48% | +110.0% | |
| OBSV | OBSEVA SA | $11,375,000 | -57.9% | 4,586,563 | 0.0% | 0.48% | -55.6% | |
| XENE | XENON PHARMACEUTICALS INC | $10,983,000 | -11.7% | 992,107 | 0.0% | 0.46% | -7.0% | |
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $8,697,000 | -44.4% | 4,141,308 | 0.0% | 0.37% | -41.5% | |
| SYBX | SYNLOGIC INC | $8,543,000 | -0.5% | 4,229,410 | 0.0% | 0.36% | +4.9% | |
| MRKR | MARKER THERAPEUTICS INC | $7,500,000 | -27.5% | 5,000,000 | 0.0% | 0.32% | -23.6% | |
| LUMO | LUMOS PHARMA INC | $7,278,000 | -16.2% | 526,663 | 0.0% | 0.31% | -11.7% | |
| ERYP | ERYTECH PHARMA SAadr | $3,750,000 | -34.4% | 625,000 | 0.0% | 0.16% | -30.9% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $3,430,000 | -27.8% | 2,382,286 | 0.0% | 0.14% | -24.1% | |
| MLND | MILLENDO THERAPEUTICS INC | $2,880,000 | -7.4% | 1,766,779 | 0.0% | 0.12% | -2.4% | |
| TCON | TRACON PHARMACEUTICALS INC | $1,793,000 | +163.7% | 346,718 | 0.0% | 0.08% | +181.5% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,055,000 | -24.6% | 2,052,455 | 0.0% | 0.04% | -19.6% | |
| AKTX | AKARI THERAPEUTICS PLCadr | $787,000 | -20.2% | 452,167 | 0.0% | 0.03% | -17.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.